Shots: J&J acquires Momenta in all-cash transaction at a price of $52.50/ share, making a total deal value as $6.5B. The transaction is expected to be closed in H2’20 The […]readmore
Tags : Acquire
Shots: Sanofi to acquire Principia Biopharma in an all-stock transaction, at $100/share making total deal value ~$3.68B in cash. The transaction is expected to be completed in Q4’20 The focus […]readmore
Shots: The acquisition will expand Medtronic’s capabilities to serve people using multiple daily injections (MDI) to manage diabetes with the addition of Companion Medical’s InPen to Medtronic’s portfolio. The acquisition […]readmore
Shots: Ligand to acquire all outstanding shares of Pfenex for $12/share in cash or $438 million in equity value with a 57% premium to the closing price of Pfenex’s stock […]readmore
Shots: KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020 The acquisition will add KaNDy’s menopause […]readmore
Shots: The acquisition will expand Olympus’ offerings in GI therapeutic devices and the development of advanced colonoscopy tools with the aim of improving early detection and treatment of CRC Olympus […]readmore
Shots: Siemens Healthineers to acquire Varian in an all-cash transaction, at a price of $177.50/ share with 42% to the 30-day volume-weighted average closing price of Varian’s common stock as […]readmore
Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission […]readmore
Shots: Gilead invests $300M to obtain 49.9% equity interest in Tizona and receives an exclusive option to acquire remaining stakes of Tizona for up to an additional $1.25B that includes […]readmore
Shots: GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research, development, manufacturing, and commercialization of up to five mRNA-based vaccines and mAbs targeting […]readmore